FAKTOR-OPTIONSSCHEIN - HALEON Stock

Certificat

DE000MG1K2T9

Real-time Bid/Ask 07:10:15 2024-05-24 am EDT
10.21 EUR / 10.23 EUR +4.07% Intraday chart for FAKTOR-OPTIONSSCHEIN - HALEON
Current month+2.08%
1 month+0.61%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-24 10.19 +3.77%
24-05-23 9.82 -2.09%
24-05-22 10.03 +1.72%
24-05-21 9.86 +1.96%
24-05-20 9.67 -2.52%

Delayed Quote Börse Stuttgart

Last update May 24, 2024 at 06:58 am EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying HALEON PLC
Issuer Morgan Stanley
WKN MG1K2T
ISINDE000MG1K2T9
Date issued 2024-04-03
Strike 496.6 p
Maturity Unlimited
Parity 0.2 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.79
Lowest since issue 9.52
Spread 0.02
Spread %0.20%

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
-
More about the company

Ratings for Haleon plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Haleon plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.289 GBP
Average target price
3.62 GBP
Spread / Average Target
+10.06%
Consensus